TY  - GEN
AU  - Krupashankar,D S
AU  - Dogra,Sunil
AU  - Kura,Mahendra
AU  - Saraswat,Abir
AU  - Budamakuntla,Leelavathy
AU  - Sumathy,T K
AU  - Shah,Radha
AU  - Gopal,M G
AU  - Narayana Rao,T
AU  - Srinivas,C R
AU  - Bhat,Ramesh
AU  - Shetty,Narendra
AU  - Manmohan,G
AU  - Sai Krishna,Kotla
AU  - Padmaja,Dalavoi
AU  - Pratap,Dasiga Venkata Subrahmanya
AU  - Garg,Vijay
AU  - Gupta,Sandesh
AU  - Pandey,Neeraj
AU  - Khopkar,Uday
AU  - Montero,Enrique
AU  - Ramakrishnan,M S
AU  - Nair,Pradip
AU  - Ganapathi,Prasanna C
TI  - Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study
SN  - 1097-6787
PY  - 2015///0122
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - therapeutic use
KW  - Chronic Disease
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Intention to Treat Analysis
KW  - Male
KW  - Middle Aged
KW  - Psoriasis
KW  - drug therapy
KW  - Severity of Illness Index
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.jaad.2014.01.897
ER  -